Key Takeaways
- A year of margin compression: EBITDA margin fell 620 bps YoY to 11.3% as specialty chemical spreads collapsed, though Q4 showed a 130 bps sequential recovery.
- Specialty chemicals the clear drag: The segment posted an EBIT margin of just 0.48%, hit by inventory overhang and a raw material-to-output price mismatch, especially in Ethyl Acetate.
- Non-ibuprofen APIs are the growth engine: Metformin export volumes jumped ~60% and Paracetamol utilization hit 95%, driving a push to lift non-ibuprofen export share toward 30%–40%.
- ANVISA approval unlocks Brazil: All 10 Barnala plants are now approved, letting the company actively target the Brazilian market for non-ibuprofen products beyond existing revenue streams.
- What to watch next quarter: Whether the promised sequential recovery in specialty chemicals actually materializes, the pace of non-ibuprofen export ramp-up, and any concrete timeline for the new multi-product plant.
Segment Performance
| Segment | Trend | Commentary |
|---|---|---|
| Pharmaceuticals | ▬ Resilient | EBIT margin of 13.22%, supported by stable ibuprofen pricing at $10–$11, lower competition, and new product launches in the US and international markets. |
| Specialty Chemicals | ▼ Weak | EBIT margin of just 0.48% driven by inventory overhang, poor spreads, and a mismatch between input costs (alcohol, Acetic Acid) and final chemical prices, especially Ethyl Acetate. Volatility from Chinese players added pressure. |
- Ibuprofen stable but not growing fast: Prices held at $10–$11 with capacity utilization at 85%–90%; management expects only 10%–12% revenue growth from the molecule in FY25.
- Non-ibuprofen API volumes surging despite price drops: Metformin export volume up ~60% and Paracetamol export volume up 10%, even as Paracetamol prices fell 35%–40% and Metformin prices fell 20%–22%. Management noted these price declines corresponded with lower raw material costs.
- Paracetamol capacity is maxed out: Running at 95% utilization, prompting plans to extend capacity this financial year by a "five-digit" amount.
- Red Sea crisis pushed up other expenses: Freight and insurance costs rose for both exports and imports, plus redistribution costs increased. Exporting to regulated markets provides some hedge on logistics costs.
Mahajan: "But all these are correspondent with the reduction in raw material prices also."
Non-Ibuprofen Growth & Export Push
- Export mix set to shift materially: Non-ibuprofen is currently 80% domestic and 20% export; management expects exports to reach 25%–30% of the non-ibuprofen segment, with one statement pointing as high as 30%–40% in FY25.
- ANVISA approval is the near-term catalyst: Brazil's regulator approved all 10 manufacturing plants at Barnala. Revenue was already flowing from these plants, but the approval now lets the company actively explore the Brazilian market for non-ibuprofen products.
- Regulatory wins stacking up: Approvals received in European and other regulated markets since April 2023, and recent client plant visits are expected to convert into orders.
- FY25 revenue growth anchored by non-ibuprofen: Management expects around 40%–45% growth in the non-ibuprofen business, compared to 10%–12% in ibuprofen, with the balance coming from the chemical segment.
Singh: "Existing revenue is coming from all these product plants. The difference is that now all these products also got approved by ANVISA, Brazil. With this, we will now be able to explore the Brazilian market for these non-ibuprofen products."
Specialty Chemicals: The Problem Child
- The margin collapse was structural for the year: FY24 was described as an exceptional year for input-output price mismatch, with the segment's EBIT margin falling to 0.48% in Q4.
- Ethyl Acetate at the center of the pain: Volatility from Chinese players in alcohol and Acetic Acid raw materials crushed spreads. Ethyl Acetate prices fell ~10%, but the raw material-to-finished-good timing mismatch destroyed profitability.
- Recovery narrative is gradual: Prices have been stable for the last one and a half quarters, and management is optimistic of a recovery this year, expecting the sector to remain healthy over the upcoming two to three quarters. The segment will stay in single-digit margins, not double-digit.
- Acetic Anhydride added to the portfolio: A new product introduced last year in the chemical sector, expected to contribute some revenue share.
Capital Allocation & Project Pipeline
- Gabapentin project pivoted to a multi-product plant: Management decided against a dedicated Gabapentin facility; the asset will now operate as a multi-product plant with Gabapentin produced only on a campaign basis.
- FY24 CAPEX of ₹246 crore: Spent on infrastructure, automation, land acquisition, and environmental systems. Growth CAPEX will stay around 40%–45% going forward, with a bottom-line impact expected over the next 2–3 years.
- New location secured for future expansion: Land acquired about 30 km from the existing Barnala site in Punjab for setting up new plants. Any revenue from this new location will be over and above the ₹3,000 crore aspiration.
- Sitagliptin developed but launch is distant: The product has been validated and approved by the Indian Patent office, but no launch date is planned and it may not happen in the current financial year.
- R&D spend to inch up: Expected to increase by 1%–2% due to recent hiring.
Mahajan: "We have already informed to the stock exchanges that management has decided to change that project into the multi-product plant and for Gabapentin we will produce only on the campaign-based basis and will not have a dedicated plant."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 10%–12% upside in topline | FY25 |
| EBITDA margin | 12%–15% (target 14%–15%, but current market situation implies slight top and bottom line decrease) | FY25 |
| PAT margin | Around 7%–8% | FY25 |
| Non-ibuprofen export share | Increase to 25%–30% of non-ibuprofen segment | FY25 |
| Paracetamol capacity expansion | "Five-digit" capacity increase | FY25 |
| Revenue aspiration | ₹3,000 crore from existing products only | By 2028 |
| Specialty chemicals recovery | Sequential and gradual recovery | By end of this year |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Total income | ₹511 cr, vs ₹596 cr in Q4 FY23 and ₹529 cr in Q3 FY24 |
| EBITDA | ₹58 cr, vs ₹104 cr in Q4 FY23 and ₹53 cr in Q3 FY24 |
| EBITDA margin | 11.3%, down 620 bps YoY from 17.5%, up 130 bps QoQ |
| Net profit | ₹28 cr, vs ₹65 cr in Q4 FY23 and ₹23 cr in Q3 FY24 |
| EBIT margin – Pharmaceutical segment | 13.22% |
| EBIT margin – Specialty Chemical segment | 0.48% |
| Full-year total income (FY24) | ₹2,163 cr, vs ₹2,243 cr in FY23 |
| Full-year EBITDA (FY24) | ₹262 cr, vs ₹252 cr in FY23 |
| Full-year EBITDA margin (FY24) | 12.1%, up 90 bps from 11.2% in FY23 |
| Full-year net profit (FY24) | ₹135 cr, vs ₹140 cr in FY23 |
| Full-year exports (FY24) | ₹679 cr, grew 7% vs ₹634 cr in FY23 |
| Full-year CAPEX (FY24) | ₹246 cr, vs ₹239 cr in FY23 |
| Ibuprofen price range | $10 to $11 per kg |
| Ibuprofen capacity utilization | 85% to 90% |
| Non-ibuprofen volume increase (FY24) | 10% to 15% in capacity terms for Paracetamol, Metformin, Clopidogrel |
| Metformin export growth (FY24) | ~60% increase from last year |
| Paracetamol export growth (FY24) | 10% increase |
| Paracetamol price decline (FY24) | more than 35% to 40% during the year |
| Metformin price decline (FY24) | 20% to 22% during the year |
| Ethyl Acetate price decline (FY24) | ~10% |
| Revenue guidance (FY25) | 10% to 12% upside |
| EBITDA margin guidance (FY25) | 12% to 15% |
| PAT margin guidance (FY25) | 7% to 8%, vs ~6% in FY24 |
| Gross margin guidance (FY25) | 20% to 25% |
| CAPEX guidance (FY25) | ₹150 cr to ₹200 cr, from internal accruals |
| Non-ibuprofen share of API portfolio (FY24) | ~40% |
| Non-ibuprofen export mix (current) | 20% export, 80% domestic; expected to reach 30% to 40% in FY25 |
| R&D headcount | 125 people |
| R&D expenses | 7% to 8% of API segment revenue, expected to increase by 1% to 2% |
| Revenue aspiration (FY28) | ₹3,000 cr, from existing products, growing 12% to 13% annually |